Drug Index


Mechanism :

Meropenem: Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins
Vaborbactam is a beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases (e.g., K. pneumonia carbapenemase [KPC]).

Indication :

  • Treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex in patients ≥18 years of age.

Contraindications :

Hypersensitivity to meropenem, vaborbactam, other carbapenems or beta-lactamase inhibitors, or any component of the formulation; patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial agents.

Dosing :

Safety and efficacy not established in pediatric population.
4 g (2 g meropenem and 2 g vaborbactam) IV every 8 hours for up to 14 days.

Adverse Effect :

Phlebitis, headache, hypokalemia, diarrhea, nausea, increased serum AST/ALT, hypersensitivity, infusion site reaction, fever.

Interaction :

Probenecid: May increase the serum concentration of Meropenem.
Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.

Hepatic Dose :

No dosage adjustments are recommended.
12/21/2023 21:33:32 Meropenem/Vaborbactam
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0